GSK Q2 Beat: £1.9B Cost Cuts to Fund 20+ Phase III Trials

GSK (GSK) reported second-quarter turnover of £8.41 billion on July 28, beating consensus of £8.24 billion, and launched a £1.9 billion ($2.52 billion) cost-savings program to fund the most aggressive late-stage pipeline expansion in the company’s history. Shares rose 6% to close at $51.98.

The numbers

• Ticker: GSK
• Stock price: $51.98 (close July 28, 2026)
• Market cap: $104.1 billion
• Q2 turnover: £8.41 billion (+5% at constant exchange rates)
• Core EPS: 50.5p (beating 47.1p consensus)
• Cost-savings program: £1.9 billion annual savings targeted by 2029, costing £2.4 billion to execute
• Phase III trial starts: 20+ planned in 2026, up from a previous target of 10

Specialty medicines led the quarter with £3.8 billion in sales (+14%), driven by HIV at £2.1 billion (+10%) and oncology at £0.6 billion (+17%). Vaccines contributed £2.3 billion (+8%). General medicines declined 9% to £2.3 billion. The results included a £1.33 billion impairment for camlipixant, the chronic cough drug that failed in the camlipixant CALM-2 failure.

The pipeline bet

GSK identified 7 assets for acceleration across 18 indications in oncology, respiratory, hepatology, and vaccines. The standout is bepirovirsen, an antisense oligonucleotide for chronic hepatitis B with a PDUFA date of October 26, 2026. The FDA granted Priority Review and Breakthrough Therapy designation in April.

The B-Well 1 and B-Well 2 Phase 3 trials, published in the New England Journal of Medicine, demonstrated functional cure rates of 19 to 20% in the overall population versus 0% with standard of care. In patients with lower baseline HBsAg levels (under 1000 IU/ml), representing roughly 45% of diagnosed cases, the functional cure rate rose to 26%. Current standard of care achieves functional cure in under 1% of patients. GSK licensed bepirovirsen from Ionis Pharmaceuticals in 2019; Ionis earns 10 to 12% tiered royalties on net sales.

Beyond bepirovirsen, the accelerated assets include two B7-H3 and B7-H4 ADCs (risvutatug rezetecan and mocertatug rezetecan), neladalkib for ALK-positive lung cancer, and expanded Jemperli use in rectal cancer. GSK also acquired two late-stage lung cancer medicines this quarter: Jideytro, which received FDA approval as a ROS1 inhibitor, and neladalkib, with a PDUFA in the second half of 2026.

Why this matters

This is a strategic pivot timed to offset the dolutegravir HIV patent cliff starting in 2028. GSK is cutting costs now to reinvest in late-stage R&D, betting that 7 accelerated assets can deliver the growth that replaces HIV revenue as generics erode that franchise. The £40 billion revenue-by-2031 target depends on it. The cost-savings program, costing £2.4 billion to execute with £2.1 billion in cash costs, will partially cushion margins through the 2028 to 2030 patent expiry period.

The cautionary tale is sitting in the same earnings release. Camlipixant, the P2X3 antagonist acquired in the $2 billion Bellus Health buyout, just failed in Phase 3 and was written off. Not every pipeline bet pays off. GSK is doubling down on the same strategy that produced that failure: paying for late-stage assets and accelerating them.

What to watch

The near-term catalyst is bepirovirsen on October 26. If approved, it would be the first therapy to deliver clinically meaningful functional cure rates in chronic hepatitis B, a disease affecting 250 million people worldwide. GSK projects peak sales exceeding £2 billion. Watch for the FDA’s review and any advisory committee scheduling. The risk: the B-Well trials excluded patients with higher HBsAg levels, and the FDA could narrow the label to the lower-HBsAg subgroup where the cure rate was 26%, limiting the addressable population.

Sources: GSK Q2 2026 press release, Reuters coverage, bepirovirsen FDA acceptance

What It Means for the Trade

The £1.9 billion cost program funding 20-plus Phase 3 starts is a self-funded re-rating bet: cut £2.4 billion in costs to buy 18 shots across 7 accelerated assets, because the dolutegravir HIV cliff starting 2028 must be replaced before it arrives. The stock’s 6% pop on the print reflects the beat (turnover £8.41 billion, core EPS 50.5p) plus the credibility of finally articulating the bridge. Every catalyst now runs through a dated calendar: bepirovirsen’s October 26 PDUFA is first and biggest — a functional-cure HBV approval would be genuinely first-in-class with peak sales projected above £2 billion — followed by neladalkib’s H2 2026 PDUFA and the ADC asset readouts. The trade framing for the next 15 months is simple: GSK has converted itself into a catalyst-dense story, and each Phase 3 start and PDUFA is a markable event. The camlipixant write-off sitting in the same release is the required caveat — this exact strategy of paying for late-stage assets produced that failure.

Mechanism and Market Context

Bepirovirsen is the portfolio’s linchpin: an antisense oligonucleotide targeting HBV messenger RNA, cutting production of the viral antigens that keep chronic hepatitis B locked in immune tolerance — the functional-cure mechanism. The B-Well trials’ published numbers define the opportunity: 19-20% functional cure in the overall population versus 0% on standard of care, rising to 26% in the lower-HBsAg subgroup that represents roughly 45% of diagnosed cases, against under 1% cure with current therapy in a disease affecting 250 million people. That is the scale gap that justifies the whole acceleration program. The mechanism logic extends to the rest of the seven: the B7-H3/B7-H4 ADCs (ris-rez among them) carry multi-tumor potential in the post-checkpoint oncology landscape, and the lung-cancer additions — Jideytro approved, neladalkib filed — give oncology near-term revenue to compound behind HIV’s £2.1 billion quarterly engine (+10%) while the patent clock runs. Specialty medicines growing 14% is the proof the mix shift is already working.

Risks and What Could Go Wrong

1. Bepirovirsen’s label could be narrowed to the low-HBsAg subgroup (26% cure, 45% of patients), shrinking the addressable population under the £2 billion peak-sales model.
2. Cost programs costing £2.4 billion to save £1.9 billion have execution risk; synergy shortfalls would crimp the reinvestment math.
3. The 2028 dolutegravir cliff is structural — if the accelerated assets slip, there is no Plan B revenue.
4. Camlipixant is the base-rate reminder: paying up for late-stage assets carries Phase 3 failure risk, and the £40 billion 2031 target has already absorbed one write-off.